Top Analyst Reports For Alphabet, Wells Fargo & PetroChina

 | Mar 22, 2019 02:38AM ET

Friday, March 22, 2019

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Alphabet (NASDAQ:GOOGL), Wells Fargo (WFC), and PetroChina (PTR). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see

Alphabet's shares have outperformed the Zacks Internet Services industry in the past year (+20.4% vs. -4.6%).The Zacks analyst thinks Alphabet is riding on its growing search initiatives. Its strong initiatives toward elimination of bad ads and introducing useful major search updates are acting as tailwinds. These are enhancing its search results.

Further, Google’s robust mobile search is also a major positive. Additionally, its strong focus toward bolstering presence in the cloud market on the back of expanding data centers and robust cloud offerings continues to aid top-line growth.

The company’s strong focus on innovation related to its AI techniques and Android OS along with growing presence in the home automation space are aiding business growth further. However, the company’s growing litigation issues might hurt its profitability. Also, it's increased spending on consumer gadgets, YouTube video app and cloud computing services remains a concern.

(You can ).

Get The News You Want
Read market moving news with a personalized feed of stocks you care about.
Get The App

Shares of Wells Fargo have underperformed the Zacks Major Regional Banks industry over the past three months (up +14.4% vs. +17.4%).Its earnings surprise history is decent, having beaten expectations in two of the trailing four quarters. The Zacks analyst likes the ongoing investments in the businesses to enhance compliance and risk management capability, build a better bank and strengthen core infrastructure.

The bank settled fake account scandal-related lawsuit filed by shareholders and ended investigations by about 50 states, which will enable it to focus on operations. However, Wells Fargo was slapped with several sanctions, including a cap on its assets by the Federal Reserve, following its involvement in several legal issues. Its reputation was harmed by such involvement and might take some time to recover. Falling mortgage banking income is another concern.

(You can ).

Get The News You Want
Read market moving news with a personalized feed of stocks you care about.
Get The App

PetroChina’s shares have gained +11.2% year to date, underperforming the Zacks International Integrated Oil industry, which has increased +13.6% over the same period. The Zacks analyst thinks that since higher oil prices will likely support the state-run giant's upstream unit in the near-to-medium term, the stock might regain favor.

The company's exploration & production segment has been benefiting from steady commodity price recovery and stricter cost control. Meanwhile, the downstream business -- consisting of the refining and chemicals’ activities – should be able to take advantage of optimized resource allocation, strict cost control and increased production of high-value products.

However, the company's weak oil production growth prospects are a major concern. Limited international operations and losses on gas imports give investors more reason to be cautious about the stock.

(You can ).

Get The News You Want
Read market moving news with a personalized feed of stocks you care about.
Get The App

Other noteworthy reports we are featuring today include Micron (MU), Tesla (NASDAQ:TSLA) and Allstate (ALL).

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

Mark Vickery

Senior Editor

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly

Today's Must Read/h6

Featured Reports/h6

Per the Zacks analyst, strong growth in managed NAND products is driving revenue growth of Micron's Mobile Business Unit. However, adverse memory and storage pricing remain concerns

Per the Zacks analyst, growing Service business on the back of strategic buyouts and expansion have ed to significant growth. However, high debt remains a concern.

Per the Zacks analyst, Tesla gains from solid strides in vehicle production, deliveries and infrastructure. Also, its focus on adding energy storage capacity is boosting growth momentum.

The Zacks analyst is upbeat about Quest Diagnostics (NYSE:DGX) on the expanded long-term pact with UnitedHealthcare, to operate as the latter's preferred national laboratory. Unit price headwinds remain.

Per the Zacks analyst, Lamar's efforts to upgrade its portfolio will raise display occupancy and advertising rates. Buyouts will also position the company for long-term growth.

Per the Zacks analyst, asset under management inflows and inorganic growth strategy will support Invesco's revenues.

The Zacks analyst appreciates the company's efforts to modernize its fleet.

New Upgrades/h6

Per the Zacks analyst, growing top line on the back of strategic buyouts such as AdvancedMD, ACTIVE Network and Heartland Payments Systems poise it well for long-term growth.

Per the Zacks analyst, Twilio's strong core voice and messaging products are leading to a robust expansion of its existing clientele and first-time deals with the new ones, thereby aiding its topline.

Per the Zacks analyst, solid traction of Macquarie Infrastructure's Atlantic Aviation segment, led by rise in hangar rental income and ancillary services revenue bodes well for its growth momentum.

New Downgrades/h6

Per the Zacks analyst, Eastman Chemical faces headwinds from raw material cost inflation. Also, weak demand for its specialty products in China remains a concern.

Per the Zacks analyst, Conagra grapples with lower sales in the Foodservice unit. The unit's sales fell 8.5% year on year in the third quarter, mainly due to the divestiture of the Trenton facility.

The Zacks analyst believes the considerable long-term debt load of $2.3 billion limits SemGroup's growth prospects. Continuing volume weakness in the company's U.S. gas unit is also a concern.

Zacks Investment Research

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Sign out
Are you sure you want to sign out?
NoYes
CancelYes
Saving Changes